- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01123590
Characteristics of Patients With Thymoma in Chulalongkorn Hospital
November 21, 2010 updated by: Chulalongkorn University
Characteristics of Patients With Thymoma Undergone Thymectomy in Chulalongkorn Hospital Between 2003-2007
The purpose of this study is to study characteristics of patients with thymoma in Chulalongkorn hospital between 2003-2007.
Study Overview
Status
Completed
Detailed Description
To study characteristics of patients with thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007 in terms of clinical manifestations, associated diseases, and laboratory findings.
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand, 10330
- Faculty of Medicine, Chulalongkorn University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007
Description
Inclusion Criteria:
- Patients with histocytological proved thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Thymoma
Patients with thymoma
|
Control
Normal controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Thymoma staging and clinical manifestations
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Associated diseases and laboratory findings Immunological data
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jettanong Klaewsongkram, MD, Chulalongkorn University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
May 12, 2010
First Submitted That Met QC Criteria
May 13, 2010
First Posted (Estimate)
May 14, 2010
Study Record Updates
Last Update Posted (Estimate)
November 23, 2010
Last Update Submitted That Met QC Criteria
November 21, 2010
Last Verified
November 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chula-ARC 003/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma Staging
-
IRCCS San RaffaeleCompletedThymoma | Computed Tomography | Prognostic Factors | Histology | Staging
-
University of ZurichCompletedNeoplasm StagingSwitzerland
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Guangzhou Institute of Respiratory DiseaseNot yet recruitingStaging IV NSCLCChina
-
Centre hospitalier de l'Université de Montréal...Completed
-
Prof. Dr. Berthold SchalkeCrolll GmbhCompletedPrimary Inoperable Thymoma | Local Recurrent ThymomaGermany
-
University of Rome Tor VergataUniversity Of Perugia; University of L'AquilaCompletedBladder Cancer TNM Staging Primary Tumor (T) Ta | Bladder Cancer TNM Staging Primary Tumor (T) T1 | Bladder Cancer Transitional Cell GradeItaly